Published in Hematology Am Soc Hematol Educ Program on January 01, 2005
How I treat essential thrombocythemia. Blood (2010) 1.75
Essential thrombocythemia. Orphanet J Rare Dis (2007) 1.32
Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagn (2007) 0.91
Integrative Multi-omic Analysis of Human Platelet eQTLs Reveals Alternative Start Site in Mitofusin 2. Am J Hum Genet (2016) 0.83
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2011) 0.78
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica (2013) 0.76
Multiple esophageal variceal ruptures with massive ascites due to myelofibrosis-induced portal hypertension. World J Gastroenterol (2012) 0.75
The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms. Int J Environ Res Public Health (2015) 0.75
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
International network of cancer genome projects. Nature (2010) 20.35
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 4.60
The myeloproliferative disorders. N Engl J Med (2006) 4.30
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood (2006) 2.98
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
Transcriptional regulation of the stem cell leukemia gene (SCL)--comparative analysis of five vertebrate SCL loci. Genome Res (2002) 2.77
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO J (2002) 2.40
Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol (2010) 2.32
Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood (2004) 2.30
Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell (2011) 2.30
Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci U S A (2007) 2.15
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood (2004) 2.11
Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci U S A (2002) 2.08
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood (2006) 2.08
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood (2005) 1.92
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood (2005) 1.91
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica (2007) 1.83
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol (2013) 1.82
Analysis of multiple genomic sequence alignments: a web resource, online tools, and lessons learned from analysis of mammalian SCL loci. Genome Res (2004) 1.80
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
How I treat essential thrombocythemia. Blood (2010) 1.75
DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol (2007) 1.66
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood (2008) 1.59
In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood (2004) 1.58
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood (2003) 1.54
Janus kinase deregulation in leukemia and lymphoma. Immunity (2012) 1.52
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood (2012) 1.52
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood (2007) 1.51
Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development. Hum Mol Genet (2005) 1.43
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol (2007) 1.42
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
The SCL transcriptional network and BMP signaling pathway interact to regulate RUNX1 activity. Proc Natl Acad Sci U S A (2007) 1.36
The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype. Blood (2006) 1.35
The transcription factors Scl and Lmo2 act together during development of the hemangioblast in zebrafish. Blood (2006) 1.34
Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer. Blood (2006) 1.32
Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells. Blood (2005) 1.26
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol (2010) 1.25
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol (2012) 1.23
The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1. Mol Cell Biol (2004) 1.22
Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol (2003) 1.20
JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood (2013) 1.18
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica (2008) 1.18
Comparative and functional analyses of LYL1 loci establish marsupial sequences as a model for phylogenetic footprinting. Genomics (2003) 1.17
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood (2010) 1.16
Identifying gene regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites. Genome Res (2006) 1.13
Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci U S A (2004) 1.11
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood (2003) 1.10
ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood (2009) 1.09
Analyses of the extent of shared synteny and conserved gene orders between the genome of Fugu rubripes and human 20q. Genome Res (2002) 1.09
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol (2009) 1.09
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol (2010) 1.08
Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol (2006) 1.07
Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol (2014) 1.05
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med (2008) 1.04
Real-time PCR mapping of DNaseI-hypersensitive sites using a novel ligation-mediated amplification technique. Nucleic Acids Res (2007) 1.03
Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood (2011) 1.03
CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol (2014) 1.03
Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica (2008) 1.00
Guideline for the diagnosis and management of myelofibrosis. Br J Haematol (2012) 0.99
Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech (2011) 0.98
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol (2010) 0.97
Transgenic analysis of the stem cell leukemia +19 stem cell enhancer in adult and embryonic hematopoietic and endothelial cells. Stem Cells (2005) 0.96
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood (2003) 0.95
Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood (2011) 0.95
Three distinct patterns of histone H3Y41 phosphorylation mark active genes. Cell Rep (2012) 0.95
A novel mode of enhancer evolution: the Tal1 stem cell enhancer recruited a MIR element to specifically boost its activity. Genome Res (2008) 0.94
Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med (2006) 0.94
The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica (2006) 0.94
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol (2014) 0.94
Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program (2009) 0.93
Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia. Blood (2010) 0.92
Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. Br J Haematol (2004) 0.91
Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol (2007) 0.91
Manipulation of mouse hematopoietic progenitors by specific retroviral infection. J Biol Chem (2003) 0.91
cis-Regulatory remodeling of the SCL locus during vertebrate evolution. Mol Cell Biol (2010) 0.90
SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica (2009) 0.89
L3mbtl, the mouse orthologue of the imprinted L3MBTL, displays a complex pattern of alternative splicing and escapes genomic imprinting. Genomics (2005) 0.87
Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia. Haematologica (2013) 0.87
Rescue of the lethal scl(-/-) phenotype by the human SCL locus. Blood (2002) 0.86
The role of the stem cell leukemia (SCL) gene in hematopoietic and endothelial lineage specification. J Hematother Stem Cell Res (2002) 0.85
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood (2012) 0.85
RFP represses transcriptional activation by bHLH transcription factors. Oncogene (2005) 0.85
Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. J Clin Invest (2013) 0.85
Transcriptional link between blood and bone: the stem cell leukemia gene and its +19 stem cell enhancer are active in bone cells. Mol Cell Biol (2006) 0.83
Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica (2006) 0.82